Australia markets close in 4 hours 13 minutes

NeuroScientific Biopharmaceuticals Limited (NSB.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.03800.0000 (0.00%)
As of 04:10PM AEDT. Market open.
Currency in AUD

Valuation measures4

Market cap (intra-day) 5.49M
Enterprise value 540.84k
Trailing P/E 17.27
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.03
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.27

Trading information

Stock price history

Beta (5Y monthly) 0.57
52-week change 3-36.67%
S&P500 52-week change 332.65%
52-week high 30.0780
52-week low 30.0330
50-day moving average 30.0393
200-day moving average 30.0429

Share statistics

Avg vol (3-month) 3230.45k
Avg vol (10-day) 3382.17k
Shares outstanding 5144.6M
Implied shares outstanding 6152.64M
Float 8103.65M
% held by insiders 134.84%
% held by institutions 14.24%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 June 2024
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 14.66%
Operating margin (ttm)66.31%

Management effectiveness

Return on assets (ttm)1.81%
Return on equity (ttm)6.46%

Income statement

Revenue (ttm)2.21M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-41.70%
Gross profit (ttm)N/A
EBITDA 246.61k
Net income avi to common (ttm)324.21k
Diluted EPS (ttm)0.0000
Quarterly earnings growth (yoy)-21.90%

Balance sheet

Total cash (mrq)4.95M
Total cash per share (mrq)0.03
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)58.87
Book value per share (mrq)0.04

Cash flow statement

Operating cash flow (ttm)44.25k
Levered free cash flow (ttm)-190.98k